Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Clinical pharmacology of thalidomide.

Eriksson T, Björkman S, Höglund P.

Eur J Clin Pharmacol. 2001 Aug;57(5):365-76. Review.

PMID:
11599654
2.

Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.

Breitkreutz I, Anderson KC.

Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):973-85. doi: 10.1517/17425255.4.7.973 . Review.

PMID:
18624684
3.

Clinical pharmacokinetics of thalidomide.

Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL.

Clin Pharmacokinet. 2004;43(5):311-27. Review.

PMID:
15080764
4.

Thalidomide: current and potential clinical applications.

Calabrese L, Fleischer AB.

Am J Med. 2000 Apr 15;108(6):487-95. Review.

PMID:
10781782
5.
6.

Thalidomide: a remarkable comeback.

Jacobson JM.

Expert Opin Pharmacother. 2000 May;1(4):849-63. Review.

PMID:
11249521
7.

Dermatologic and nondermatologic uses of thalidomide.

Nasca MR, Micali G, Cheigh NH, West LE, West DP.

Ann Pharmacother. 2003 Sep;37(9):1307-20. Review.

PMID:
12921515
8.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
9.

Thalidomide: a review of approved and investigational uses.

Matthews SJ, McCoy C.

Clin Ther. 2003 Feb;25(2):342-95. Review.

PMID:
12749503
10.

Thalidomide for the treatment of multiple myeloma.

Hattori Y, Iguchi T.

Congenit Anom (Kyoto). 2004 Sep;44(3):125-36. Review.

PMID:
15327481
11.

Chirality and pharmacokinetics: an area of neglected dimensionality?

Hutt AJ.

Drug Metabol Drug Interact. 2007;22(2-3):79-112. Review.

PMID:
17708062
12.

Recent advances in analytical determination of thalidomide and its metabolites.

Bosch ME, Sánchez AJ, Rojas FS, Ojeda CB.

J Pharm Biomed Anal. 2008 Jan 7;46(1):9-17. Epub 2007 Oct 9. Review.

PMID:
18023317
13.

Palliative oncology: thalidomide.

Prommer EE.

Am J Hosp Palliat Care. 2010 May;27(3):198-204. doi: 10.1177/1049909109348981. Epub 2009 Oct 20. Review.

PMID:
19843880
14.

Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.

Renner UD, Oertel R, Kirch W.

Ther Drug Monit. 2005 Oct;27(5):655-65. Review.

PMID:
16175141
15.

Thalidomide: an antineoplastic agent.

Amato RJ.

Curr Oncol Rep. 2002 Jan;4(1):56-62. Review.

PMID:
11734114
16.

Adverse effects of thalidomide administration in patients with neoplastic diseases.

Dimopoulos MA, Eleutherakis-Papaiakovou V.

Am J Med. 2004 Oct 1;117(7):508-15. Review.

PMID:
15464708
17.

Novel biological response modifiers derived from thalidomide.

Hashimoto Y.

Curr Med Chem. 1998 Jun;5(3):163-78. Review.

PMID:
9562600
18.

Thalidomide: mechanisms of action.

Paravar T, Lee DJ.

Int Rev Immunol. 2008;27(3):111-35. doi: 10.1080/08830180801911339. Review.

PMID:
18437602
19.

Theoretical basis for the activity of thalidomide.

Meierhofer C, Dunzendorfer S, Wiedermann CJ.

BioDrugs. 2001;15(10):681-703. Review.

PMID:
11604049
20.

Supplemental Content

Support Center